Literature DB >> 18008375

Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control.

Ramin Massoumi1, Ralf Paus.   

Abstract

Analysing cylindromatosis and the associated defects in the CYLD gene is providing novel insights into the molecular principles of epithelial growth control and carcinogenesis in, and beyond, the skin. In this review, we summarize the histopathology and histogenesis of cylindromas, and the available genetic information on patients with these skin appendage tumors. Focusing on recent data concerning the normal functions and signaling interactions of the CYLD gene product, we explain how CYLD interferes with TNF-alpha or TLR-mediated signaling as well as with JNK or NF-kappaB-dependent p65/50 signaling to limit inflammation. In addition, we delineate how CYLD interferes with activation of the proto-oncogene Bcl(3) and with cyclin D1 expression to limit tumorigenesis, and chart how tumor growth-promoting agents or UV light and inflammatory mediators can activate CYLD. We argue that these recent insights into CYLD function and cylindroma pathogenesis may lead to the development of novel molecular strategies for cancer prevention and treatment. 2007 Wiley Periodicals, Inc

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18008375     DOI: 10.1002/bies.20677

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  21 in total

Review 1.  CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.

Authors:  S-C Sun
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

Review 2.  The molecular regulation of programmed necrotic cell injury.

Authors:  David Moquin; Francis Ka-Ming Chan
Journal:  Trends Biochem Sci       Date:  2010-03-26       Impact factor: 13.807

3.  The IκB family member Bcl-3 coordinates the pulmonary defense against Klebsiella pneumoniae infection.

Authors:  Frédéric Pène; Andrea Paun; Søren Ulrik Sønder; Nimisha Rikhi; Hongshan Wang; Estefania Claudio; Ulrich Siebenlist
Journal:  J Immunol       Date:  2011-01-12       Impact factor: 5.422

Review 4.  CYLD-mediated signaling and diseases.

Authors:  Bryan J Mathis; Yimu Lai; Chen Qu; Joseph S Janicki; Taixing Cui
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

5.  Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing.

Authors:  Nicola Fusco; Pierre-Emmanuel Colombo; Luciano G Martelotto; Maria R De Filippo; Salvatore Piscuoglio; Charlotte K Y Ng; Raymond S Lim; William Jacot; Anne Vincent-Salomon; Jorge S Reis-Filho; Britta Weigelt
Journal:  Histopathology       Date:  2015-06-29       Impact factor: 5.087

Review 6.  Alternative splicing in the NF-kappaB signaling pathway.

Authors:  Joshua R Leeman; Thomas D Gilmore
Journal:  Gene       Date:  2008-07-22       Impact factor: 3.688

7.  Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation.

Authors:  Eirini Trompouki; Ageliki Tsagaratou; Stylianos K Kosmidis; Pascal Dollé; Jun Qian; Dimitris L Kontoyiannis; Wellington V Cardoso; George Mosialos
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

Review 8.  Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.

Authors:  Patrick W Blake; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

Review 9.  Bcl-3, a multifaceted modulator of NF-kappaB-mediated gene transcription.

Authors:  Scott Palmer; Youhai H Chen
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.

Authors:  Sara A Wickström; Katarzyna C Masoumi; Saadi Khochbin; Reinhard Fässler; Ramin Massoumi
Journal:  EMBO J       Date:  2009-11-05       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.